Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
CYTO | US
-0.01
-2.53%
Healthcare
Biotechnology
31/03/2024
21/10/2024
0.58
0.62
0.62
0.57
Altamira Therapeutics Ltd. a clinical-and commercial-stage biopharmaceutical company engages in the development of therapeutics that address various unmet medical needs in Switzerland the United States Europe and Australia. The company develops OligoPhore/SemaPhore a platform for delivery of oligonucleotides such as small interfering ribonucleic acid or messenger RNA into target cells. Its commercial products include Bentrio a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is also developing AM-401 for the treatment of KRAS driven cancer; AM-411 for the treatment of rheumatoid arthritis; AM-125 that is in phase II clinical trial for the treatment of vertigo; Keyzilen which is in phase III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. The company was founded in 2003 and is headquartered in Hamilton Bermuda.
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Negative Momentum (Declining Price)
Weakness based on declining price with high volume
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
56.4%1 month
64.0%3 months
74.7%6 months
82.5%0.32
-
0.35
0.02
0.01
-0.47
64.93
-
-5.80M
2.17M
2.17M
-
-
-
-63.70
-368.78
0.30
0.63
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.07
Range1M
0.18
Range3M
0.77
Rel. volume
1.19
Price X volume
37.57K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Dermata Therapeutics Inc. Common Stock | DRMA | Biotechnology | 1.56 | 2.36M | -3.11% | n/a | 0.00% |
Allarity Therapeutics Inc. Common Stock | ALLR | Biotechnology | 1.63 | 2.30M | -5.78% | n/a | 6.68% |
60 Degrees Pharmaceuticals Inc. Common Stock | SXTP | Biotechnology | 1.07 | 1.99M | -1.83% | n/a | 5.19% |
Sorrento Therapeutics Inc | SRNE | Biotechnology | 0.003 | 1.90M | 11.11% | n/a | -101.21% |
Panbela Therapeutics Inc | PBLA | Biotechnology | 0.3354 | 1.76M | 5.14% | 0.00 | -39.69% |
Kiromic BioPharma Inc | KRBP | Biotechnology | 1.1 | 1.70M | -8.33% | n/a | -258.59% |
Innovation Pharmaceuticals Inc | IPIX | Biotechnology | 0.003 | 1.56M | 200.00% | n/a | 20.48% |
CohBar Inc | CWBR | Biotechnology | 0.5 | 1.45M | 0.00% | n/a | 0.00% |
Arch Therapeutics Inc | ARTH | Biotechnology | 0.3002 | 1.33M | 0.00% | n/a | 0.00% |
TC BioPharm (Holdings) plc American Depositary Shares | TCBP | Biotechnology | 2.27 | 1.30M | -55.14% | n/a | 131.42% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 3.65 | 2.01M | -6.89% | n/a | 0.00% |
Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.011 | 1.01M | 10.00% | n/a | -37.05% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -0.47 | 0.53 | Cheaper |
Ent. to Revenue | 64.93 | 3,967.00 | Cheaper |
PE Ratio | 0.32 | 41.03 | Cheaper |
Price to Book | 0.35 | 15.55 | Cheaper |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 74.66 | 72.80 | Par |
Debt to Equity | 0.02 | -1.23 | Expensive |
Debt to Assets | 0.01 | 0.25 | Cheaper |
Market Cap | 2.17M | 3.66B | Emerging |